NCT01211834 - Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions

Rheumatoid Arthritis

Interventions

DRUG

tocilizumab

intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks

DRUG

DMARDs

Methotrexate(MTX) and/or 1 DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)

DRUG

Placebo

intravenously over 1 hour infusion every 4weeks

DRUG

DMARDs

Methotrexate(MTX) and/or 1 DMARDs

Trial Locations (1)

Seoul National Univ. Hospital, Seoul